Premium
Low FT3 is a valuable predictor of severe acute pancreatitis in the emergency department
Author(s) -
Yang Wei Qiang,
Yang Qian,
Chen Wan Jun,
Zhang Xiao Bin,
Xu Qing Qing,
Qiao Yun,
Xu Xin Hui,
Liu Li,
Lu Xiao Ye,
Zhu Chang Qing
Publication year - 2018
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12609
Subject(s) - medicine , emergency department , acute pancreatitis , emergency medicine , pancreatitis , intensive care medicine , medical emergency , psychiatry
OBJECTIVE To investigate the relationship between serum levels of thyroid hormones and disease severity at the early stage of acute pancreatitis (AP). METHODS Cohort data from 172 patients with AP attending the Emergency Department of our hospital from 2012 to 2017 were retrospectively reviewed and analyzed. Patients were categorized into mild (MAP), moderately severe (MSAP) and severe AP (SAP) groups based on the disease severity. The MSAP and SAP groups were combined into a non‐MAP group for analysis. The predictive values of C‐reactive protein (CRP) levels, Ranson score, APACHE II score and serum thyroid hormone levels were analyzed. RESULTS In total, 76 (44.2%), 85 (49.4%) and 11 (6.4%) patients were included in the MAP, MSAP and SAP groups, respectively. The free triiodothyronine (FT3) levels were significantly lower in the combined non‐MAP group than in the MAP group. The tetraiodothyronine (T4) levels were significantly lower in the SAP group than in the MAP and MSAP groups ( P = 0.002). Logistic regression analysis revealed that a low FT3 level was an independent risk factor for the incidence of non‐MAP ( P = 0.004). The area under the receiver operating characteristic curve and sensitivity of FT3 were 0.729 and 88.2%, respectively, which were higher than those of CRP, Ranson and APACHE II scores. CONCLUSION Monitoring FT3 levels in the early stage of AP is helpful for evaluating disease severity and predicting the incidence of non‐MAP, making it a useful tool for guiding AP treatment.